NBSE · Neubase Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $21.45M | $11.48M | $6.95M | $4.27M | $4.32M | $17.41M |
| SG&A | $11.87M | $12.20M | $10.12M | $9.10M | $3.63M | $5.28M |
| Total Operating Expenses | $33.32M | $26.57M | $17.07M | $26.34M | - | - |
| D&A | $400.0K | $403.0K | $280.5K | $128.4K | $1.12M | $1.17M |
| Operating Income | ($33.32M) | ($26.57M) | ($17.07M) | ($26.34M) | ($13.90M) | ($23.78M) |
| Interest Expense | $24.0K | $32.3K | $7.7K | $129.0K | - | - |
| Income Tax | - | - | - | $0 | ($23.81M) | - |
| Net Income | ($33.78M) | ($25.41M) | ($17.38M) | ($26.96M) | ($13.24M) | ($23.81M) |
| EPS - Basic | ($1.04) | ($0.89) | - | - | - | - |
| EPS - Diluted | ($1.04) | ($0.89) | - | - | - | - |
Balance Sheet
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $23.15M | $52.89M | $31.99M | $10.31M | $3.75M | $12.80M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.84M | $1.81M | $1.51M | $21.7K | - | - |
| Current Assets | $24.65M | $54.93M | $32.81M | $11.03M | $4.00M | $13.02M |
| Total Assets | $32.69M | $64.17M | $34.44M | $12.53M | $11.63M | $27.93M |
| Current Liabilities | $4.17M | $4.19M | - | $2.50M | $725.0K | $4.93M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $9.50M | $10.10M | $3.15M | $2.50M | $725.0K | $5.08M |
| Stockholders' Equity | $23.19M | $54.07M | $31.29M | $10.03M | $10.90M | $22.84M |
| Retained Earnings | ($102.74M) | ($68.97M) | ($43.56M) | ($27.00M) | ($121.33M) | ($108.09M) |
Cash Flow
| Line item | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($29.01M) | ($18.87M) | ($10.71M) | ($2.85M) | ($9.49M) | ($15.99M) |
| Investing Cash Flow | ($471.7K) | ($2.56M) | ($716.8K) | ($685.2K) | $528.0K | ($14.5K) |
| Financing Cash Flow | ($257.0K) | $42.34M | $33.11M | $13.60M | ($86.3K) | ($150.0K) |
| CapEx | $471.7K | $1.44M | $716.8K | $455.2K | - | $4.8K |
| Free Cash Flow | ($29.48M) | ($20.31M) | ($11.43M) | ($3.30M) | - | ($15.99M) |
Ratios
| Metric | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 0.87 | 0.80 | 0.66 | 0.12 | - | 0.67 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -103.3% | -39.6% | -50.5% | -215.1% | -113.9% | -85.3% |
| Return on equity | -145.6% | -47.0% | -55.6% | -268.8% | -121.4% | -104.2% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 5.92 | 13.10 | - | 4.41 | 5.52 | 2.64 |
| Quick ratio | 5.92 | 13.10 | - | 4.41 | 5.52 | 2.64 |
| Cash ratio | 5.56 | 12.61 | - | 4.12 | 5.17 | 2.59 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -1385.6x | -821.7x | -2220.8x | -204.2x | - | - |
| Equity multiplier | 1.41 | 1.19 | 1.10 | 1.25 | 1.07 | 1.22 |
| Liabilities / Assets | 0.29 | 0.16 | 0.09 | 0.20 | 0.06 | 0.18 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | - | - | - | - | - | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | -25.4% | -55.6% | 35.2% | -89.4% | 41.5% | 3.3% |
| Net income growth (YoY) | -32.9% | -46.2% | 35.5% | -103.7% | 44.4% | 7.6% |
| EPS growth (YoY) | -16.9% | - | - | - | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | -45.2% | -77.8% | -246.2% | - | - | 0.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -57.1% | 72.8% | 212.0% | -8.0% | -52.3% | -8.5% |
Stability scores
Piotroski F-score
FY 2022 · 9-point quality
1/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✗No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing NeuBase Therapeutics against the 5 most active filers in the same SIC group.